Daiichi Sankyo Company Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Daiichi Sankyo Company de 22% y 12.8% por año respectivamente. Se prevé que el BPA crezca en un 22.5% al año. Se espera que la rentabilidad financiera sea de 16.7% en 3 años.

Información clave

18.7%

Tasa de crecimiento de los beneficios

18.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.5%
Tasa de crecimiento de los ingresos	10.9%
Rentabilidad financiera futura	17.7%
Cobertura de analistas	Good
Última actualización	07 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Recent updates

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

Previsiones de crecimiento de beneficios e ingresos

TSE:4568 - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	2,312,461	349,315	269,257	381,719	10
3/31/2026	2,054,743	264,301	162,555	298,511	14
3/31/2025	1,762,062	188,620	126,394	236,505	14
3/31/2024	1,601,688	200,731	476,467	599,258	N/A
12/31/2023	1,503,471	186,052	509,483	601,669	N/A
9/30/2023	1,397,025	147,885	-79,581	4,025	N/A
6/30/2023	1,348,996	147,350	15,149	89,040	N/A
3/31/2023	1,278,478	109,188	47,148	114,514	N/A
12/31/2022	1,182,201	59,354	52,831	120,225	N/A
9/30/2022	1,122,724	62,816	85,820	153,864	N/A
6/30/2022	1,061,140	50,603	74,484	148,554	N/A
3/31/2022	1,044,892	66,972	62,544	139,226	N/A
12/31/2021	1,034,692	94,470	91,294	161,092	N/A
9/30/2021	1,012,313	86,756	52,721	111,874	N/A
6/30/2021	989,638	79,321	58,547	106,238	N/A
3/31/2021	962,516	75,958	128,114	192,207	N/A
12/31/2020	963,552	70,599	123,806	188,054	N/A
9/30/2020	982,388	116,315	132,076	206,119	N/A
6/30/2020	969,501	117,584	96,878	174,904	N/A
3/31/2020	981,793	129,074	144,036	196,601	N/A
12/31/2019	983,669	148,891	137,641	212,138	N/A
9/30/2019	962,440	113,821	120,648	187,666	N/A
6/30/2019	953,219	112,805	113,638	181,424	N/A
3/31/2019	929,717	93,409	25,420	92,033	N/A
12/31/2018	922,228	66,479	38,321	85,284	N/A
9/30/2018	937,648	70,018	49,447	97,072	N/A
6/30/2018	946,829	55,081	56,120	96,957	N/A
3/31/2018	960,195	60,282	70,431	108,439	N/A
12/31/2017	961,766	37,887	N/A	99,826	N/A
9/30/2017	966,509	38,758	N/A	83,608	N/A
6/30/2017	953,255	52,017	N/A	102,946	N/A
3/31/2017	955,124	53,466	N/A	136,234	N/A
12/31/2016	962,296	59,736	N/A	161,540	N/A
9/30/2016	965,681	60,572	N/A	184,039	N/A
6/30/2016	989,001	77,951	N/A	181,513	N/A
3/31/2016	986,446	82,282	N/A	174,281	N/A
12/31/2015	839,759	55,256	N/A	139,346	N/A
9/30/2015	872,744	67,132	N/A	146,907	N/A
6/30/2015	903,340	61,708	N/A	151,239	N/A
3/31/2015	919,372	46,762	N/A	142,776	N/A
12/31/2014	1,149,342	88,276	N/A	N/A	N/A
9/30/2014	1,127,233	80,437	N/A	119,883	N/A
6/30/2014	1,120,177	69,910	N/A	N/A	N/A
3/31/2014	1,118,241	60,943	N/A	37,304	N/A
12/31/2013	1,059,287	90,021	N/A	N/A	N/A
9/30/2013	1,030,096	73,097	N/A	46,961	N/A
6/30/2013	1,007,747	57,234	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.9% al año) de 4568 es superior a la tasa de ahorro (0.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.9% al año) de 4568 crezcan más rápidamente que el mercado JP (9.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 4568 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (12.8% al año) de 4568 crezcan más rápidamente que los del mercado JP (4.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.8% al año) de 4568 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 4568 sea baja dentro de 3 años (16.7%).

Daiichi Sankyo Company Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Recent updates

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Upcoming dividend of JP¥17.00 per share at 0.9% yield

European Union Recommends ENHERTU for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited and AstraZeneca PLC Announce Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Daiichi Sankyo Announces First Patient Dosed in a First-In-Human Phase 1/2 Trial Evaluating DS-3939 in Patients with Several Types of Advanced Solid Cancers

Daiichi Sankyo Company, Limited's ENHERTU Receives Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Daiichi Sankyo Company, Limited to Report Q2, 2024 Results on Oct 31, 2023

Daiichi Sankyo Company, Limited Announces Vanflyta® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Daiichi Sankyo Company, Limited Announces FDA Approves VANFLYTA (Quizartinib) in Combination with Standard Cytarabine and Antibody Indication

Daiichi Sankyo Company, Limited to Report Q1, 2024 Results on Jul 31, 2023

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento